The Information Professional’s Role in Product Safety

Slides:



Advertisements
Similar presentations
What FDA Looks for When Inspecting IRBs and Sponsors Marian J. Serge Nurse Consultant Division of Bioresearch Monitoring Office of Compliance Center for.
Advertisements

The Information Professionals Role in Product Safety Jack Leitmeyer Director, Adverse Experience Information Management Worldwide Product Safety Merck.
Tips to a Successful Monitoring Visit
Radiopharmaceutical Production
What is involved? What are your responsibilities? May 2013: Research Institute, Clinical Research Administration Investigational New Drug Application (IND)
Regulatory Compliant Performance Improvement for Pharmaceutical Plants AIChE New Jersey Section 01/13/2004 Murugan Govindasamy Pfizer Inc.
GCP compliance for GenISIS  This presentation is intended for clinical staff involved in recruiting patients to the GenISIS (Genetics of Influenza Susceptibility.
Pharmacists Responsibilities in Clinical Studies Mike R Sather, PhD Crystal L Harris, PharmD February 26, 2004.
IRB-Investigator/ Research Coordinator Mtg. “CUMC’s New Progressive Policy For Adverse Event Reporting” April 13, 2004 George Gasparis Andrew Wit, Ph.D.
CUMC IRB Investigator Meeting Human Subjects Research Non-Compliance September 15, 2005.
Pharmaceutical Development and Review Process Rev. 10/21/2014 APGO Interaction with Industry: A Medical Student Guide.
+ Drug Development and Review Process. + Objectives Learn the processes involved in drug discovery and development Define the phases involved in FDA drug.
Session 6: Data Integrity and Inspection of e-Clinical Computerized Systems May 15, 2011 | Beijing, China Kim Nitahara Principal Consultant and CEO META.
Investigational New Drug Application 21 CFR Part 312 A Review for OCRA US RAC Study Group September 2005 Ginger Clasby, MS Promedica International
Monitoring and Special Considerations for Multi-Center Trials
11 February 2008NLM BOR WG on Clinical Trials1 Clinical Trials Registration and Results Reporting: Legislative Requirements Jerry Sheehan Assistant Director.
Recapture of Day 1 Suchart Chongprasert, Ph.D. Food and Drug Administration “Practical Aspects in Performing Clinical and Bioanalytical Parts in BA/BE.
Justina A. Molzon, MS Pharm, JD
Pharmacovigilance obligations of the Pharmaceutical companies in India
Adverse Events and Unanticipated Problems Presented by: Karen Jeans, PhD, CCRN, CIP COACH Program Analyst.
Industry Perspective on Challenges for Product Developers - Drugs Christine Allison, M.S., RAC Associate Regulatory Consultant, Global Regulatory Affairs.
Elements of Clinical Trial Quality Assurance Regulatory Coordinator –SCTR SUCCESS Center QA Monitor – NIDA Clinical Trials Network Stephanie Gentilin,
Fourth Annual Medical Research Summit Concurrent Session 4.05 – Managing CROs and SMOs from a Compliance Perspective Michael SwiatochaAprill 23, 2004.
Investigational New Drug Application (IND)
Joint Research & Enterprise Office Training The team, the procedures, the monitor and the Sponsor Lucy H H Parker Clinical Research Governance Manager.
Case Study: Pharmaceuticals Patrick F. Sullivan, Ph.D. 939 North Graham Avenue, Indianapolis, IN
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
CLINICAL TRIALS – PHASE III. What are phase III trials  Confirmatory phase (Therapeutic confirmatory trial)  Trials are done to obtain sufficient evidence.
1/33.  What is INDA ?  Types of INDAs  Objectives of INDAs  Format & Contents of an INDA  IND Safety reports  IND Annual Reports  IND Review Process.
Overview of Gene Therapy Surveillance Inspections Joseph P Salewski, Chief Bioresearch Monitoring Branch CBER.
Korea Food & Drug Administration Deputy director Kwang-Soo Joo Korea FDA Sep. 29, 2000 : Korean Good Clinical Practice & Relative Guidelines How to Manage.
GCP (GOOD CLINICAL PRACTISE)
Responsibilities of Sponsor, Investigator and Monitor
1 SAE Centralized Report and Review Process April 2012.
Cancer Clinical Trials Office Clinical Trials & Research Training Oct2014.
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
Dartmouth Human Research Protection Program (HRPP) Data Safety Monitoring and Reporting requirements Brown Bag Series: Noon / First Tuesday of the Month.
FDAAA Clinical Trial Disclosure Briefing for GCP/QA SIAC
ClinicalTrials.gov Requirements

Responsibilities of Sponsor, Investigator and Monitor
MAINTAINING THE INVESTIGATOR’S SITE FILE
Regulatory– Terms & Definitions רגולציה - מונחים והגדרות
Clinicaltrials.gov Update
CTD Content Management
How to Put Together an IDE Application
EudraVigilance.
How to Apply for and Receive Industry Funding for Investigator Sponsored Research Chuck Simonton MD, FACC, FSCAI Chief Medical Officer Abbott Vascular.
Alyssa Speier, MS, CIP November 13, 2013
ClinicalTrials.gov: An introduction
Adverse Event Reporting: Trials and Tribulations
Jennifer S. Novia INFO 643 March 6, 2011
Pharmacovigilance in clinical trials
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
UK Legal Requirement for Notification of Serious Breaches of Good Clinical Practice or The Trial Protocol John Poland, PhD Senior Director, Regulatory.
Quality System.
HOW TO FULFILL STATUTORY REQUIREMENTS ON PRODUCT RELATED HEALTH INFORMATION Samina Qureshi, M.D. PSI INTERNATIONAL Inc.
The Most Important Element to Assure That Your Sales and Marketing Compliance Program is Working Effectively: Monitoring and Auditing Kelly B. Freeman,
SERIOUS ADVERSE EVENTS REPORTING
FDA 21 CFR Part 11 Overview June 10, 2006.
FDA Resources and Meetings
Fundamentals of Electronic Submissions and eCTD
MAINTAINING THE INVESTIGATOR’S STUDY FILE
IND Review Process Seoul National University
Timothy B. Cleary, Esq. Meredith Manning, Esq.
Opening an IND: Investigator Perspective
Code of Ethics for CDM Professionals
Computer System Validation
Code of Ethics for CDM Professionals
Radiopharmaceutical Production
Presentation transcript:

The Information Professional’s Role in Product Safety Jack Leitmeyer Director, Adverse Experience Information Management Worldwide Product Safety Merck & Co., Inc.

Agenda Importance of Safety Surveillance Regulatory Requirements Role of the Adverse Experience (AE) Information Professional Future Opportunities

Importance of Safety Surveillance Compliance with Government Laws and Regulations Timely and Accurate Monitoring of the Safety Profile of Products Limitation of human data in clinical trials Small study populations Restricted enrollment Limited long term safety data Widespread use of the product in the post-marketing environment Benefit–risk safety profile changes over time

Adverse Experience Reporting to FDA Pre-Approval - To IND 7 calendar day reports (telephone or facsimile) Unexpected fatal or life-threatening experience associated with the use of the drug 15 calendar day reports to IND From All Studies Worldwide (Serious, Drug-Related and Unexpected) Findings from tests in laboratory animals suggesting a significant risk to humans (mutagenicity, teratogenicity, carcinogenicity) Spontaneous Reports from Marketing Outside the U.S. (Serious and Unexpected) Reports in the scientific literature including unpublished manuscripts (Serious and Unexpected) Reports from foreign regulatory authorities (Serious and Unexpected) Annual IND reports From Studies Worldwide (Serious)

Adverse Experience Reporting to FDA Post-Approval - To IND 15 calendar day reports to IND From IND Studies (Serious, Drug-Related and Unexpected) Annual IND Report From IND Studies (Serious) Post-Approval - To NDA 15 calendar day reports to NDA From All Studies Worldwide (Serious, Drug-Related and Unexpected) Spontaneous Reports Worldwide (Serious and Unexpected) Periodic Reports to NDA

Failure to Report Pre-Approval - Termination of IND 21 CFR 312.44 Phase 1, 2 or 3 (b)(1)(vii) “The sponsor fails promptly to investigate and inform the Food and Drug Administration and all investigators of serious and unexpected adverse experiences in accordance with part 312 section 32 or fails to make any other report required under this part.”

Failure to Report Post-Approval- Withdrawal of NDA 21 CFR 314.80 (K) “If an applicant fails to establish and maintain records and make reports required under this section FDA may withdraw approval of the application and, thus, prohibit continued marketing of the drug product that is the subject of the application.”

Business Impact Product People Monetary Loss Penalties per Violation (Section 303 FD&C Act) Fines and/or Jail

AE Information Management Call Center Reports / Queries Data Mining Applications Regulatory Submission database Clinical (MedDRA) / Drug Dictionaries Investigator Portal AE database Clinical Risk Mgt. Clinical Trial data Regulatory Agencies Imaging System Business Partners Product Labeling Clinical Literature

Role of the AE Information Professional Helpful Experience: Clinical terminology Worldwide safety regulations Technology Six Sigma Methodology

Role of the AE Information Professional Safety Database Oversight Reference Data Management Document Management Dictionary Management Queries / Reports Quality Control

Role of the AE Information Professional Safety Database Oversight Information moving electronically between business partners and regulatory agencies Managing large datasets (over a million episodes) Mapping data fields across systems What data are required by safety department and regulatory agencies Algorithms for information flow Routing algorithms for data entry Routing to countries / agencies / business partners Rules for reportability

Role of the AE Information Professional Safety Database Oversight – ICH E2B ICH = International Conference on Harmonization ICH E2B - Standardized essential data elements for electronic transmission of individual case safety reports: Patient characteristics Reactions/Events Results of tests and procedures relevant to investigation of patient Drug(s) Information (e.g., status, generic, tradename, marketing authorization number) Narrative Case Summary (e.g., case summary, sender’s opinion of overall diagnosis/syndrome or reclassification of reporter terms)

Role of the AE Information Professional Reference Data Management Clinical Trial protocol and site numbers Allocation schedules Drug formulations Routes of administration Country Lists NDA / IND numbers Journal Titles etc.

Role of the AE Information Professional Document Management Record Retention Policy “Official” Files – paper / electronic records Patient Privacy Access to shared procedures Access to training material

Role of the AE Information Professional Dictionary Management Medical Dictionary for Drug Regulatory Activities (MedDRA*) Company procedures related to global standard dictionary Feedback to MedDRA Maintenance and Support Services Organization (MSSO) Participation in Industry User Group Drug Dictionary * MedDRA® is a registered trademark of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).

Role of the AE Information Professional Queries / Reports Provide output for monitoring product safety and responding to safety questions. Ensure proper validation and testing (21 CFR Part 11) Information Specialist can provide input on: What data fields are available ? Search all versions, latest versions, or latest completed versions? Have the data values changed over time as regulations, procedures, and databases have changed ? What MedDRA terms / term groupings should be used to query the database ? What is the best format for the output? What is correct skill set required for writing and executing database queries?

Role of the AE Information Professional Quality Control Data Entry sampling Coding Review Electronic submission tracking Compliance monitoring

Future Opportunities Evolving Regulations Global Harmonization Electronic Transfer of Data Links to External Databases Data Mining